SCHEMBL3494974

SCHEMBL3494974

O=c1[nH]c(Cc2ccccc2C(F)(F)F)nc2c(-c3cccnc3)n[nH]c12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AR P10275 1/20 0.41
▸ RAB9A P51151 1/20 0.39
▸ CACNA1H O95180 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ PDE9A O76083 2/20 0.38
▸ PDE1A P54750 1/20 0.38
▸ PDE1B Q01064 1/20 0.38
▸ PDE1C Q14123 1/20 0.38
▸ NPY5R Q15761 1/20 0.38
▸ P2RX7 Q99572 1/20 0.37
▸ IDO1 P14902 1/20 0.36
▸ LRRK2 Q5S007 1/20 0.36
▸ AKR1B1 P15121 1/20 0.35
▸ CLK2 P49760 2/20 0.35
▸ CLK3 P49761 2/20 0.35
▸ DYRK1A Q13627 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6367719 0.90 CACNA1H (0.39) CACNA1HALDH1A1LMNAPOLBHPGD
SCHEMBL3492777 0.87 PDE9A (0.54) ALDH1A1POLBPDE9APDE1APDE1B
SCHEMBL6367003 0.83 HCRTR1 (0.43) CACNA1HALDH1A1LMNAPOLBHPGD
SCHEMBL6371987 0.81 PDE9A (0.40) ALDH1A1POLBHPGDPDE9APDE1A
SCHEMBL6366070 0.81 PDE9A (0.44) ALDH1A1L3MBTL1PDE9APDE1APDE1B
SCHEMBL6368276 0.80 PIM1 (0.39) ARIDO1LRRK2CLK2CLK3
SCHEMBL6372381 0.80 NTRK1 (0.41) IDO1LRRK2CLK2CLK3DYRK1A
SCHEMBL3493363 0.79 PDE9A (0.55) ALDH1A1POLBPDE9APDE1APDE1B
SCHEMBL3493936 0.78 MEN1 (0.43) ARIDO1LRRK2CLK2CLK3
SCHEMBL6366628 0.76 PDE9A (0.53) ARLMNAPDE9APDE1APDE1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1440073-A1 PDE9 INHIBITORS FOR TREATING CARDIOVASCULAR DISORDERS Pfizer Limited (GB) 2004-07-28 — — EP claimed
US-20030195205-A1 PDE9 inhibitors for treating cardiovascular disorders PFIZER INC. 2003-10-16 — — US claimed
WO-2003037899-A1 PDE9 INHIBITORS FOR TREATING CARDIOVASCULAR DISORDERS PFIZER LIMITED (GB) 2003-05-08 — — WO claimed
US-20100113484-A1 TREATING AGENT OF UROPATHY ASKA PHARMACEUTICAL CO., LTD. (JP) 2010-05-06 — — US disclosed
EP-2123301-A1 THERAPEUTIC AGENT FOR URINARY TRACT DISEASE ASKA Pharmaceutical Co., Ltd. (JP) 2009-11-25 — — EP disclosed
EP-1440073-A1 PDE9 INHIBITORS FOR TREATING CARDIOVASCULAR DISORDERS Pfizer Limited (GB) 2004-07-28 — — EP disclosed
US-20030195205-A1 PDE9 inhibitors for treating cardiovascular disorders PFIZER INC. 2003-10-16 — — US disclosed
WO-2003037899-A1 PDE9 INHIBITORS FOR TREATING CARDIOVASCULAR DISORDERS PFIZER LIMITED (GB) 2003-05-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113484-A1 TREATING AGENT OF UROPATHY BPHL, PDE12, UROD AR 1877/4885RAB9A 231/4885CACNA1H 2208/4885
US-20030195205-A1 PDE9 inhibitors for treating cardiovascular disorders PDE9A, PDE2A, PDE3A AR 300/4885RAB9A 249/4885CACNA1H 1481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback